Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

Journal of gastrointestinal cancer - 1 Dec 2016

Silkin Sergey V, Startsev Sergey S, Krasnova Marina E, Raskin Grigory A, Mitiushkina Natalia V, Iyevleva Aglaya G, Sokolenko Anna P, Imyanitov Evgeny N

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin
Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Irinotecan

Share to Panitumumab

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 26687137
DOI: 10.1007/s12029-015-9792-2

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.PMID 26687137Read ↗

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read ↗

Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.Semantic proximity Read ↗

Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.Semantic proximity Read ↗

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.Semantic proximity Read ↗

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple MyelomaSemantic proximity Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.